I-Mab Signs an Exclusive License Agreement with MacroGenics to Develop and Commercialize Enoblituzumab in Greater China

Shots:

• MacroGenics to receive $15M up front, up to $135M as development & regulatory milestones and royalties on sales in Greater China. I-Mab to get development & commercialization rights for Enoblituzumab in China, Hong Kong, Macau and Taiwan
• As per the agreement, I-Mab will lead global clinical studies including its territories. In H2’19, MacroGenics plans to initiate P-II study of enoblituzumab + MGA012 (licensed to Incyte Corporation) as 1L therapy for head and neck cancer
• Enoblituzumab is mAb incorporating MacroGenics’ Fc Optimization technology platform that targets B7-H3 which regulates the immune response in multiple cancer. Fc-optimization technology modulates an Ab interaction with immune effector cell affecting the killing of cancer cells through ADCC

Click here to read full press release/ article | Ref: MacroGenics | Image: Linkedin